CPT code 64612 represents unilateral chemical neurolysis of the facial nerve performed to relieve painful facial nerve disorders or to reduce abnormal involuntary facial movements. As a targeted interventional procedure, it matters nationally because it is used when medical therapies are insufficient and can affect utilization of outpatient surgical services, procedural coding accuracy, and payer coverage determinations for facial pain and movement disorders.

Key payers commonly considered in coverage and reimbursement discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical and coding overview, typical sites of service and service type, and a summary of the payer landscape and common billing considerations. The content addresses how the procedure is categorized in procedural coding, typical clinical indications, and where to expect the service to be delivered.

This publication aims to provide clinicians, billers, and policy analysts with clear context for CPT code 64612, including benchmarks related to service delivery and payer coverage norms where available, plus any relevant policy updates or coding guidance impacting national reimbursement and utilization trends.